Lecanemab Favors Early Aggregates. Fluorescently labeled lecanemab (green) bound most strongly to soluble Aβ aggregates ...

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

A new Alzheimer’s drug has been rejected by the health spending watchdog for general use within NHS England, with the ...

Donanemab is a targeted antibody drug which slows down the early stages of Alzheimer’s. The drug, and another new drug for ...

For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

The pharma giant Eli Lilly is currently in the process of preparing their own submission to Nice for appraisal of their Alzheimer’s drug donanemab. Just like lecanemab, genetic testing would ...

The decision on donanemab – the second drug found to slow the progress of Alzheimer’s disease – is set to mirror one taken in August when lecanemab, the first breakthrough treatment for the ...

One described the approval of lecanemab as “no panacea” for patients, for example, while another went as far as to suggest that, in their eyes, donanemab offered “no net benefit” at all.

A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending ...